Guggenheim Initiates Coverage On Tourmaline Bio with Buy Rating, Announces Price Target of $50
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yatin Suneja has initiated coverage on Tourmaline Bio (NASDAQ:TRML) with a Buy rating and a price target of $50.
October 31, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim has initiated coverage on Tourmaline Bio with a Buy rating and a price target of $50, which could positively impact the stock's performance.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, Guggenheim's Buy rating and $50 price target for Tourmaline Bio suggest a positive outlook for the company, which could attract more investors and drive up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100